MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma
MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma
复制标题
DOI：
10.1111/j.1442-2042.2012.03182.x
复制
发表时间：
2013-05-01
影响因子：
2.6
通讯作者：
Yasui, Wataru
中科院分区：
文献类型：
--
作者：
Shinmei, Shunsuke;Sakamoto, Naoya;Yasui, Wataru
目的探讨微小核糖核酸-155（micro-ribonucleic acid-155，miRNA-155）在肾透明细胞癌中的临床意义，特别是其表达水平与肾透明细胞癌患者的临床病理因素、肿瘤特异性生存率和治疗结局的关系。方法采用定量逆转录聚合酶链反应（RT-PCR）技术，对137例肾透明细胞癌患者的77对肾透明细胞癌组织和癌旁正常肾组织进行了微量核糖核酸-155定量检测。结果与正常肾组织相比，微小核糖核酸-155在肾透明细胞癌组织中的表达明显增高。micro-ribonucleic acid-155的表达与所有分期组的预后无关。然而，在43例III期和IV期肾透明细胞癌患者中，micro-ribonucleic acid-155的低表达水平与不良预后相关。关于26例接受根治性切除术的III期和IV期透明细胞肾细胞癌患者的无癌生存率和31例接受根治性肾切除术后干扰素治疗的患者的癌症特异性生存率，这两组中微核糖核酸-155的低表达水平与不良临床结局相关。结论微小核糖核酸-155的低表达是III期和IV期肾透明细胞癌患者临床预后不良的一个有价值的标志。
Objectives To investigate the clinical significance of micro-ribonucleic acid-155 in clear cell renal cell carcinoma, in particular focusing on the association of expression levels of micro-ribonucleic acid-155 with clinicopathological factors, cancer-specific survival and therapeutic outcomes in clear cell renal cell carcinoma patients. Methods Quantitative reverse transcription polymerase chain reaction of micro-ribonucleic acid-155 was carried out on 137 clear cell renal cell carcinoma cases, containing 77 matched pairs of clear cell renal cell carcinoma and normal adjacent kidney tissues from the same patients. Results Significant overexpression of micro-ribonucleic acid-155 was found in clear cell renal cell carcinoma compared with normal kidney tissue. Expression of micro-ribonucleic acid-155 was not associated with prognosis in all stage groups. However, in 43 patients with stageIII and IV clear cell renal cell carcinoma, low expression levels of micro-ribonucleic acid-155 correlated with a poor prognosis. Regarding cancer-free survival of 26 patients with stageIII and IV clear cell renal cell carcinoma who received curative resection and cancer-specific survival of 31 patients who received postoperative therapy with interferon- after radical nephrectomy, low expression levels of micro-ribonucleic acid-155 correlated with poor clinical outcomes in these two groups. Conclusions Low expression of micro-ribonucleic acid-155 represents a valuable marker of poor clinical outcomes in patients with stageIII and IV clear cell renal cell carcinoma.